Effector Stock Analysis

EFTR -  USA Stock  

USD 5.45  0.05  0.93%

The modest gains experienced by current holders of Effector Therapeutics could raise concerns from retail investors as the firm it trading at a share price of 5.45 on 27,881 in volume. The company management teams have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in December. The stock standard deviation of daily returns for 90 days investing horizon is currently 11.75. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Effector Therapeutics partners.
Continue to Investing Opportunities.

Effector Stock Analysis 

 
Refresh
The Effector Therapeutics stock analysis report makes it easy to digest most publicly released information about Effector Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Effector Stock analysis module also helps to analyze the Effector Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Effector Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.1. Effector Therapeutics had not issued any dividends in recent years. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company was founded in 2012 and is headquartered in San Diego, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To learn more about Effector Therapeutics call the company at 858 925 8215 or check out https://effector.com.

Effector Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Effector Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Effector Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Effector Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 1.16 M. Net Loss for the year was (3.65 M) with profit before overhead, payroll, taxes, and interest of 20.17 M.
Effector Therapeutics currently holds about 54.77 M in cash with (27.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36.
Effector Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 69.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.marketscreener.com: Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 and Vascular Endothelial Growth Factor A - marketscreener.com

Effector Therapeutics Upcoming and Recent Events

Earnings reports are used by Effector Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Effector Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report14th of February 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End14th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Effector Largest EPS Surprises

Earnings surprises can significantly impact Effector Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-08
2021-09-30-0.20.420.62310 
View All Earnings Estimates

Effector Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Effector Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Effector Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Effector Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
8th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
1st of November 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
13th of September 2021
Unclassified Corporate Event
View
7th of September 2021
Unclassified Corporate Event
View
3rd of September 2021
Unclassified Corporate Event
View
25th of August 2021
Unclassified Corporate Event
View
24th of August 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
View
23rd of August 2021
Other Events
View

Effector Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Effector Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Effector Therapeutics backward and forwards among themselves. Effector Therapeutics' institutional investor refers to the entity that pools money to purchase Effector Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Parallel Advisors LlcWarrants3.3 KK
Abingworth LlpCommon Shares4.8 M67 M
Column Group LlcCommon Shares4.3 M60.5 M
Sectoral Asset Management IncCommon Shares2.9 M40.5 M
Blackstone IncCommon Shares1.3 M18.4 M
Whitebox Advisors LlcCall Options218.4 K350 K
Verition Fund Management LlcCommon Shares24.7 K347 K
Geode Capital Management LlcCommon Shares24 K337 K
Jane Street Group LlcCommon Shares18.3 K257 K
Note, although Effector Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Effector Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 218.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Effector Therapeutics's market, we take the total number of its shares issued and multiply it by Effector Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Effector Profitablity

Effector Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Effector Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Effector Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Effector Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Effector Therapeutics' profitability requires more research than a typical breakdown of Effector Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets 0.0135  0.0134 
Return on Average Equity(0.0009) (0.000971) 
Return on Invested Capital 7.84  7.79 
Return on Sales 0.34  0.34 

Management Efficiency

As of 01/27/2022, Return on Average Assets is likely to drop to 0.0134. In addition to that, Return on Average Equity is likely to drop to -0.001. As of 01/27/2022, Assets Non Current is likely to grow to about 116.4 K, while Total Assets are likely to drop slightly above 16.4 M. Effector Therapeutics management efficiency ratios could be used to measure how well effector therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2022
Book Value per Share(10.41) (11.23) 
Tangible Assets Book Value per Share 1.32  1.15 
Tangible Asset Value19.2 M16.4 M

Technical Drivers

As of the 27th of January, Effector Therapeutics shows the Coefficient Of Variation of 6081.49, downside deviation of 5.75, and Mean Deviation of 4.08. Effector Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Effector Therapeutics, which can be compared to its rivals. Please confirm Effector Therapeutics variance, as well as the relationship between the value at risk and skewness to decide if Effector Therapeutics is priced favorably, providing market reflects its regular price of 5.45 per share. Given that Effector Therapeutics has jensen alpha of 0.1872, we urge you to verify Effector Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Effector Therapeutics Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Effector Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Effector Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Effector Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Effector Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Effector Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Patel Premal 3 days ago via Macroaxis 
Acquisition by Patel Premal of 150000 shares of Effector Therapeutics subject to Rule 16b-3
Gallagher Brian M Jr over a month ago via Macroaxis 
Acquisition by Gallagher Brian M Jr of 40000 shares of Effector Therapeutics subject to Rule 16b-3
Presidio Management Group X Llc over a month ago via Macroaxis 
Sale by Presidio Management Group X Llc of 252 shares of Effector Therapeutics
Presidio Management Group X Llc over a month ago via Macroaxis 
Sale by Presidio Management Group X Llc of 597 shares of Effector Therapeutics
Presidio Management Group X Llc over two months ago via Macroaxis 
Sale by Presidio Management Group X Llc of 156 shares of Effector Therapeutics
Presidio Management Group X Llc over two months ago via Macroaxis 
Sale by Presidio Management Group X Llc of 812 shares of Effector Therapeutics
Presidio Management Group X Llc over two months ago via Macroaxis 
Sale by Presidio Management Group X Llc of 317 shares of Effector Therapeutics
Presidio Management Group X Llc over two months ago via Macroaxis 
Sale by Presidio Management Group X Llc of 372 shares of Effector Therapeutics
Klencke Barbara over two months ago via Macroaxis 
Acquisition by Klencke Barbara of 40000 shares of Effector Therapeutics subject to Rule 16b-3
Smither John W over three months ago via Macroaxis 
Acquisition by Smither John W of 40000 shares of Effector Therapeutics subject to Rule 16b-3
Bhatt Elizabeth over three months ago via Macroaxis 
Acquisition or disposition of Effector Therapeutics securities by Bhatt Elizabeth
Sr One Capital Management Llc over three months ago via Macroaxis 
Effector Therapeutics exotic insider transaction detected

Effector Therapeutics Predictive Daily Indicators

Effector Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Effector Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Effector Therapeutics Forecast Models

Effector Therapeutics time-series forecasting models is one of many Effector Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Effector Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Effector Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Effector Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Effector shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Effector Therapeutics. By using and applying Effector Stock analysis, traders can create a robust methodology for identifying Effector entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.34  0.34 
Gross Margin 0.90  0.89 
Profit Margin 0.0036  0.003579 
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK12 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer . The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A , which is in phase 12 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.

Current Effector Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Effector analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Effector analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
30.75Strong Buy4Odds
Effector Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Effector analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Effector stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Effector Therapeutics, talking to its executives and customers, or listening to Effector conference calls.
Effector Analyst Advice Details

Effector Stock Analysis Indicators

Effector Therapeutics stock analysis indicators help investors evaluate how Effector Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Effector Therapeutics shares will generate the highest return on investment. By understating and applying Effector Therapeutics stock analysis, traders can identify Effector Therapeutics position entry and exit signals to maximize returns.
Quick Ratio1.21
Fifty Two Week Low5.20
Revenue Growth-25.60%
Shares Short Prior Month174.37k
Average Daily Volume Last 10 Day31.01k
Average Daily Volume In Three Month133.19k
Shares Percent Shares Out0.46%
Forward Price Earnings-5.93
Float Shares9.82M
Fifty Two Week High40.42
Enterprise Value To Ebitda-11.49
Fifty Day Average7.37
Two Hundred Day Average10.35
Enterprise Value To Revenue248.06
Continue to Investing Opportunities. Note that the Effector Therapeutics information on this page should be used as a complementary analysis to other Effector Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Effector Stock analysis

When running Effector Therapeutics price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Effector Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.